Citing the impact of COVID-19, Insmed (NASDAQ:INSM) has suspended its 2020 revenue guidance of $180M – 220M.
On the positive side, it has filed a marketing
application in Japan for Arikayce (amikacin liposome inhalation
suspension) for the treatment of patients with non-tuberculous
mycobacterial lung disease caused by Mycobacterium avium complex who
failed to adequately respond to prior treatment.
AstraZeneca (NYSE:AZN)
has exercised the first option in their October 2016 license agreement,
electing to advance INS1007 for the potential treatment of chronic
obstructive pulmonary disease (COPD) or asthma through Phase 2b
development. It retains the option to further advance INS1007 for COPD
or asthma contingent on mutual agreement on commercial terms. Insmed
retains the rights for all other indications.
https://seekingalpha.com/news/3552246-insmed-suspends-revenue-guidance-amid-coronavirus-outbreak-uncertainty
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.